Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest HeartMate Stories

2012-08-14 02:29:59

NEW YORK, Aug. 14, 2012 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced full FDA approval of its Pivotal Trial for evaluation of the Jarvik 2000® heart for destination therapy (DT) named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD Effectiveness). (Photo: http://photos.prnewswire.com/prnh/20120227/NY60355 ) Use of the device for DT means that it will provide long-term, permanent support to...

2012-07-24 02:28:28

PLEASANTON, Calif., July 24, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the second quarter of fiscal year 2012 on Wednesday, August 1. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time...

2012-06-26 02:28:15

PLEASANTON, Calif., June 26, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced the launch of Thoratec Connect(TM), the first Cloud-based advanced MCS program management system. Thoratec Connect is designed to meet the needs of the ventricular assist device (VAD) teams who provide care to the growing population of MCS patients. HeartMate II®,...

2012-06-01 06:23:33

PLEASANTON, Calif., June 1, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Tuesday, June 5, the company will participate in the Goldman Sachs Global Healthcare Conference. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at...

2012-05-24 02:27:49

TUCSON, Ariz., May 24, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the SynCardia temporary Total Artificial Heart has recently replaced left ventricular assist devices (LVADs) in seven patients suffering from end-stage heart failure. (Photo: http://photos.prnewswire.com/prnh/20120524/LA13121) An LVAD is a continuous-flow, mechanical pump...

2012-05-09 02:27:09

PLEASANTON, Calif., May 9, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 4:20 p.m., Pacific Daylight Time (7:20 p.m., Eastern Daylight...

2012-05-08 10:27:02

FRAMINGHAM, Mass. and SYDNEY, May 8, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that enrollment is complete in ENDURANCE, the Company's pivotal Destination Therapy clinical study to evaluate the use of the HeartWare® Ventricular Assist System in patients with end-stage heart failure....

2012-04-20 02:22:34

PLEASANTON, Calif., April 20, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2012 on Tuesday, May 1. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight...

2012-04-17 02:29:24

PLEASANTON, Calif., April 17, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced that as of April 2012, clinicians have implanted more than 10,000 HeartMate II® Left Ventricular Assist Devices (LVADs) in patients suffering from advanced heart failure (AHF) worldwide. The HeartMate II is a small implantable mechanical device that helps...

2012-04-07 23:01:36

Parker Waichman LLP is warning patients about the dangers of Thoratec´s HeartMate II Left Ventricular Assist System (LVAS). Although the Class I recall implies that there potentially fatal complications, the “recalled” device remains on the market. Following reports of improper detachment at the bend relief component, the FDA is concerned that the defect “may cause serious adverse health consequences, including death”. Port Washigton, NY (PRWEB) April 07, 2012...